Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Development of Antibiotic Resistance

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Mechanism of Antibiotic Resistance in MRSA

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quantifying the impact of individual and collective compliance with infection control measures for ethical public health policy.

Science advances·2023

Same author

Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.

Vaccine·2022

Same author

Reconciling Regulation with Scientific Autonomy in Dual-Use Research.

The Journal of medicine and philosophy·2022

Same author

Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.

Vaccine·2020

Same author

Invisible epidemics: ethics and asymptomatic infection.

Monash bioethics review·2020

Same author

Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?

Journal of medical ethics·2020

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Ethics and drug resistance.

Michael J Selgelid¹

¹Centre for Applied Philosophy and Public Ethics (CAPPE), and Menzies Centre for Health Policy, The Australian National University, LPO Box 8260, ANU Canberra ACT 2601, Australia. michael.selgelid@anu.edu.au

|September 12, 2007

Summary

Drug resistance, driven by unequal antibiotic access, poses severe public health risks. This ethical issue highlights the need to treat healthcare, particularly infectious disease, as a global public good.

Area of Science:

Public Health
Bioethics
Health Economics

Background:

Drug resistance is a growing global threat due to increasing drug-resistant pathogens.
The phenomenon is intricately linked to drug distribution patterns, not just natural evolution.
Existing market-based systems fail to adequately address the externalities associated with antibiotic use.

Purpose of the Study:

To review the dynamics and ethical dimensions of drug resistance.
To examine how drug distribution influences the development of resistance.
To argue for healthcare, specifically for infectious diseases, to be considered a global public good.

Main Methods:

Literature review of the dynamics and ethical issues of drug resistance.
Analysis of the relationship between antibiotic consumption patterns (over- and under-consumption) and resistance.

More Related Videos

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

Related Experiment Videos

Last Updated: Jul 11, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

Examination of market failures and externalities in the context of drug distribution.

Main Results:

Drug resistance stems from both over-consumption by the wealthy and under-consumption by the marginalized.
The development of resistant pathogens creates negative externalities, increasing risks for third parties.
Market inefficiencies are evident, underscored by the lack of new antibiotic classes developed since 1970.

Conclusions:

Drug resistance underscores the ethical imperative to view health and infectious disease care as a global public good.
The failure of free-market distribution for goods with externalities necessitates a re-evaluation of healthcare policy.
Bioethical considerations must expand to encompass the societal impact of drug resistance and advocate for equitable distribution.